* BioRestorative Therapies Inc is expected to show a fall in quarterly revenue when it reports results on May 14 for the period ending March 31 2024
* The Melville New York-based company is expected to report a 4.2% decrease in revenue to $30 thousand from $31.3 thousand a year ago, according to the estimate from one analyst, based on LSEG data.
* LSEG's mean analyst estimate for BioRestorative Therapies Inc is for a loss of 51 cents per share.
* The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 2 "strong buy" or "buy," no "hold" and no "sell" or "strong sell."
* The mean earnings estimate of analysts had risen by about 1.4% in the last three months.
* Wall Street's median 12-month price target for BioRestorative Therapies Inc is $10.50, above its last closing price of $1.37.
This summary was machine generated May 10 at 23:38 GMT. All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)
Comments